256 related articles for article (PubMed ID: 7854186)
1. Design of tight-binding human immunodeficiency virus type 1 protease inhibitors.
Vacca JP
Methods Enzymol; 1994; 241():311-34. PubMed ID: 7854186
[No Abstract] [Full Text] [Related]
2. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.
Kempf DJ
Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187
[No Abstract] [Full Text] [Related]
3. Advances in automated docking applied to human immunodeficiency virus type 1 protease.
Miller MD; Sheridan RP; Kearsley SK; Underwood DJ
Methods Enzymol; 1994; 241():354-70. PubMed ID: 7854188
[No Abstract] [Full Text] [Related]
4. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
[TBL] [Abstract][Full Text] [Related]
5. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
6. Probing structure-function relationships in human immunodeficiency virus type 1 protease via molecular dynamics simulation.
Harte WE; Beveridge DL
Methods Enzymol; 1994; 241():178-95. PubMed ID: 7854178
[TBL] [Abstract][Full Text] [Related]
7. Qualitative study of drug resistance in retroviral protease using structural modeling and site-directed mutagenesis.
Culberson JC; Bush BL; Sardana VV
Methods Enzymol; 1994; 241():385-94. PubMed ID: 7854190
[No Abstract] [Full Text] [Related]
8. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates.
Tomasselli AG; Heinrikson RL
Methods Enzymol; 1994; 241():279-301. PubMed ID: 7854182
[No Abstract] [Full Text] [Related]
9. Use of molecular dynamics and free energy perturbation calculations in anti-human immunodeficiency virus drug design.
McCarrick MA; Kollman P
Methods Enzymol; 1994; 241():370-84. PubMed ID: 7854189
[No Abstract] [Full Text] [Related]
10. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
[TBL] [Abstract][Full Text] [Related]
12. Structure-based prediction of potential binding and nonbinding peptides to HIV-1 protease.
Kurt N; Haliloglu T; Schiffer CA
Biophys J; 2003 Aug; 85(2):853-63. PubMed ID: 12885633
[TBL] [Abstract][Full Text] [Related]
13. X-ray structures of retroviral proteases and their inhibitor-bound complexes.
Ringe D
Methods Enzymol; 1994; 241():157-77. PubMed ID: 7854176
[No Abstract] [Full Text] [Related]
14. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.
Fehér A; Weber IT; Bagossi P; Boross P; Mahalingam B; Louis JM; Copeland TD; Torshin IY; Harrison RW; Tözsér J
Eur J Biochem; 2002 Aug; 269(16):4114-20. PubMed ID: 12180988
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites.
Ridky TW; Cameron CE; Cameron J; Leis J; Copeland T; Wlodawer A; Weber IT; Harrison RW
J Biol Chem; 1996 Mar; 271(9):4709-17. PubMed ID: 8617736
[TBL] [Abstract][Full Text] [Related]
16. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
[TBL] [Abstract][Full Text] [Related]
17. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of a tethered dimer of HIV-1 proteinase complexed with an inhibitor.
Bhat TN; Baldwin ET; Liu B; Cheng YS; Erickson JW
Nat Struct Biol; 1994 Aug; 1(8):552-6. PubMed ID: 7664084
[TBL] [Abstract][Full Text] [Related]
19. A side chain at position 48 of the human immunodeficiency virus type-1 protease flap provides an additional specificity determinant.
Moody MD; Pettit SC; Shao W; Everitt L; Loeb DD; Hutchison CA; Swanstrom R
Virology; 1995 Mar; 207(2):475-85. PubMed ID: 7886951
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic.
Kiso Y
Adv Exp Med Biol; 1995; 362():413-23. PubMed ID: 8540352
[No Abstract] [Full Text] [Related]
[Next] [New Search]
